Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B1 | P15538 | 6/20 | 0.39 |
| ▸ | CYP11B2 | P19099 | 6/20 | 0.39 |
| ▸ | CYP19A1 | P11511 | 3/20 | 0.39 |
| ▸ | LRRK2 | Q5S007 | 2/20 | 0.36 |
| ▸ | SMPD1 | P17405 | 1/20 | 0.35 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.35 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | PTGER1 | P34995 | 3/20 | 0.35 |
| ▸ | PSD | A5PKW4 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | SRPK3 | Q9UPE1 | 1/20 | 0.34 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21786493 | 0.88 | PTGER1 (0.39) | MEN1KMT2APTGER1CYP2C9ALDH1A1 | |
| SCHEMBL21786627 | 0.88 | MAPT (0.41) | LRRK2MEN1HTTKMT2APTGER1 | |
| SCHEMBL21786590 | 0.86 | NPSR1 (0.36) | MEN1KMT2APTGER1ALDH1A1 | |
| SCHEMBL21786446 | 0.86 | PTGER1 (0.40) | LRRK2KMT2APTGER1CYP2C9RAB9A | |
| SCHEMBL21786420 | 0.86 | PTPN1 (0.40) | MEN1KMT2APTGER1ALDH1A1 | |
| SCHEMBL22825444 | 0.86 | PTGER1 (0.33) | MEN1KMT2APTGER1ALDH1A1RAB9A | |
| SCHEMBL21786542 | 0.86 | USP7 (0.35) | PTGER1TBXA2R | |
| SCHEMBL21786412 | 0.85 | MRGPRX4 (0.40) | LRRK2PTGER1PSDCYP2C9RAB9A | |
| SCHEMBL21786450 | 0.85 | CYP11B1 (0.39) | CYP11B1CYP11B2CYP19A1LRRK2SMPD1 | |
| SCHEMBL23913065 | 0.84 | SMN1; SMN2 (0.34) | MEN1HTTKMT2APTGER1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210395206-A1 | SUBSTITUTED HETEROCYCLES AS c-MYC TARGETING AGENTS | NORTHWESTERN UNIVERSITY | 2021-12-23 | — | — | US | disclosed |
| US-11142504-B2 | Substituted heterocycles as c-MYC targeting agents | NORTHWESTERN UNIVERSITY (US) | 2021-10-12 | — | — | US | disclosed |
| WO-2020257261-A1 | SUBSTITUTED HETEROCYCLES AS c-MYC TARGETING AGENTS | NORTHWESTERN UNIVERSITY (US) | 2020-12-24 | — | — | WO | disclosed |
| US-20200392116-A1 | SUBSTITUTED HETEROCYCLES AS c-MYC TARGETING AGENTS | NORTHWESTERN UNIVERSITY (US) | 2020-12-17 | — | — | US | disclosed |
| WO-2020046382-A1 | SUBSTITUTED HETEROCYCLES AS C-MYC TARGETING AGENTS | NORTHWESTERN UNIVERSITY (US) | 2020-03-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200392116-A1 | SUBSTITUTED HETEROCYCLES AS c-MYC TARGETING AGENTS | MYC, MYCBP, MYCBP2 | CYP11B1 3260/4885CYP11B2 3531/4885CYP19A1 3457/4885 |
| US-20210395206-A1 | SUBSTITUTED HETEROCYCLES AS c-MYC TARGETING AGENTS | MYC, MYCBP, MYCBP2 | CYP11B1 3260/4885CYP11B2 3531/4885CYP19A1 3457/4885 |
| US-11142504-B2 | Substituted heterocycles as c-MYC targeting agents | MYC, MYCBP, MYCBP2 | CYP11B1 3260/4885CYP11B2 3531/4885CYP19A1 3457/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.